The University of Chicago Header Logo

Connection

Michael Charlton to Liver Cirrhosis

Back to Details
This is a "connection" page, showing publications Michael Charlton has written about Liver Cirrhosis.
Michael Charlton
Connection Strength
10.672
Liver Cirrhosis
  1. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Clin Liver Dis. 2018 02; 22(1):201-211.
    View in: PubMed
    Score: 0.528
  2. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2017 Jun 01; 312(6):G666-G680.
    View in: PubMed
    Score: 0.495
  3. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017 04; 152(5):1090-1099.e1.
    View in: PubMed
    Score: 0.491
  4. Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management. Gastroenterology. 2016 06; 150(8):1849-62.
    View in: PubMed
    Score: 0.463
  5. Response to Fibrosis progression in patients treated for hepatitis C recurrence. Liver Int. 2015 Dec; 35(12):2625.
    View in: PubMed
    Score: 0.455
  6. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015 Nov; 35(11):2433-41.
    View in: PubMed
    Score: 0.442
  7. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59.
    View in: PubMed
    Score: 0.438
  8. Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful? Liver Int. 2015 Jan; 35(1):9-11.
    View in: PubMed
    Score: 0.427
  9. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan; 148(1):108-17.
    View in: PubMed
    Score: 0.420
  10. Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review. Liver Transpl. 2013 Dec; 19(12):1311-7.
    View in: PubMed
    Score: 0.396
  11. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2012 Mar; 18(3):323-31.
    View in: PubMed
    Score: 0.350
  12. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int. 2012 Feb; 32(2):279-86.
    View in: PubMed
    Score: 0.339
  13. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2011 Nov; 301(5):G825-34.
    View in: PubMed
    Score: 0.337
  14. Fibrosing NASH: on being a blind man in a dark room looking for a black cat (that isn't there). Gastroenterology. 2011 Jan; 140(1):25-8.
    View in: PubMed
    Score: 0.321
  15. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009 Jun; 9(6):1406-13.
    View in: PubMed
    Score: 0.289
  16. Cirrhosis and liver failure in nonalcoholic fatty liver disease: Molehill or mountain? Hepatology. 2008 May; 47(5):1431-3.
    View in: PubMed
    Score: 0.269
  17. Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon. Am J Gastroenterol. 2007 Feb; 102(2):409-11.
    View in: PubMed
    Score: 0.246
  18. Branched-chain amino-acid granules: can they improve survival in patients with liver cirrhosis? Nat Clin Pract Gastroenterol Hepatol. 2006 Feb; 3(2):72-3.
    View in: PubMed
    Score: 0.230
  19. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
    View in: PubMed
    Score: 0.200
  20. Branched-chain amino acid-enriched supplements as therapy for liver disease: Rasputin lives. Gastroenterology. 2003 Jun; 124(7):1980-2.
    View in: PubMed
    Score: 0.191
  21. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database. BMC Gastroenterol. 2023 May 19; 23(1):160.
    View in: PubMed
    Score: 0.191
  22. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation. 2000 Jul 27; 70(2):292-7.
    View in: PubMed
    Score: 0.157
  23. Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 2020 09 01; 319(3):G333-G344.
    View in: PubMed
    Score: 0.157
  24. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.
    View in: PubMed
    Score: 0.149
  25. The Triumph of Bacchus: The Emergence of Nonalcoholic Steatohepatitis and Alcoholic Liver Disease as the Leading Causes of Mortality From Cirrhosis. Hepatology. 2019 03; 69(3):931-933.
    View in: PubMed
    Score: 0.142
  26. TT-virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis. Hepatology. 1998 Sep; 28(3):839-42.
    View in: PubMed
    Score: 0.138
  27. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2018 11; 155(5):1463-1473.e6.
    View in: PubMed
    Score: 0.137
  28. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018 07; 68(1):349-360.
    View in: PubMed
    Score: 0.136
  29. Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis. J Hepatol. 2018 09; 69(3):617-625.
    View in: PubMed
    Score: 0.134
  30. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018 06; 154(8):2111-2121.e8.
    View in: PubMed
    Score: 0.133
  31. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int. 2018 10; 38(10):1849-1859.
    View in: PubMed
    Score: 0.133
  32. Hepatitis G virus infection in patients transplanted for cryptogenic cirrhosis: red flag or red herring? Transplantation. 1998 Jan 15; 65(1):73-6.
    View in: PubMed
    Score: 0.132
  33. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg. 1997 Jul; 3(4):359-64.
    View in: PubMed
    Score: 0.127
  34. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017 10; 24(10):823-831.
    View in: PubMed
    Score: 0.125
  35. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2017 03; 15(3):421-430.e6.
    View in: PubMed
    Score: 0.121
  36. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016 10; 1(2):122-132.
    View in: PubMed
    Score: 0.119
  37. Branched chains revisited. Gastroenterology. 1996 Jul; 111(1):252-5.
    View in: PubMed
    Score: 0.118
  38. On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antivir Ther. 2016; 21(6):541-546.
    View in: PubMed
    Score: 0.115
  39. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology. 2011 Sep 02; 54(3):1063-70.
    View in: PubMed
    Score: 0.084
  40. Aquaporin-1 facilitates angiogenic invasion in the pathological neovasculature that accompanies cirrhosis. Hepatology. 2010 Jul; 52(1):238-48.
    View in: PubMed
    Score: 0.078
  41. Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells. J Clin Invest. 2010 Jul; 120(7):2379-94.
    View in: PubMed
    Score: 0.078
  42. Fatty liver and liver transplantation. Clin Liver Dis. 2009 Nov; 13(4):621-30.
    View in: PubMed
    Score: 0.075
  43. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology. 2008 Feb; 47(2):484-92.
    View in: PubMed
    Score: 0.066
  44. Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006 Jun; 43(6):1177-86.
    View in: PubMed
    Score: 0.059
  45. Branched-chain amino acid enriched supplements as therapy for liver disease. J Nutr. 2006 01; 136(1 Suppl):295S-8S.
    View in: PubMed
    Score: 0.057
  46. Liver Transplantation 2023: Status Report, Current and Future Challenges. Clin Gastroenterol Hepatol. 2023 07; 21(8):2150-2166.
    View in: PubMed
    Score: 0.047
  47. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl. 2002 Apr; 8(4):362-9.
    View in: PubMed
    Score: 0.044
  48. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study. BMJ Open. 2022 03 30; 12(3):e056159.
    View in: PubMed
    Score: 0.044
  49. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl. 2001 Jul; 7(7):608-14.
    View in: PubMed
    Score: 0.042
  50. Genotype 1b and severity of posttransplant recurrence of hepatitis C infection- unconvictable felon or wrongly accused? Liver Transpl. 2000 Mar; 6(2):243-5.
    View in: PubMed
    Score: 0.038
  51. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018 02; 67(2):549-559.
    View in: PubMed
    Score: 0.033
  52. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation. 2017 05; 101(5):945-955.
    View in: PubMed
    Score: 0.031
  53. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. Transplantation. 2017 05; 101(5):956-967.
    View in: PubMed
    Score: 0.031
  54. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31; 373(27):2618-28.
    View in: PubMed
    Score: 0.028
  55. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012 Jun; 107(6):811-26.
    View in: PubMed
    Score: 0.022
  56. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol. 2007 Mar; 5(3):394-402; quiz 267.
    View in: PubMed
    Score: 0.015
  57. Clinical significance of TT virus infection in patients with chronic hepatitis C. Am J Gastroenterol. 1999 Oct; 94(10):3020-7.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.